Welcome to our dedicated page for BIORA THERAPEUTICS SEC filings (Ticker: BIOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BIORA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BIORA THERAPEUTICS's regulatory disclosures and financial reporting.
Biora Therapeutics, Inc. (BIOR) – Schedule 13G/A Amendment No. 1
Context Capital Management, LLC, together with four related reporting persons (Michael S. Rosen, William D. Fertig, Charles E. Carnegie and Context Partners Master Fund, L.P.), has filed an amended Schedule 13G reporting beneficial ownership of 22,025 BIOR common shares as of 30 June 2025. The filing cites an outstanding share count of 4,522,702 (as of 6 Nov 2024), placing the group’s holding at 0.5 % of the company’s common equity.
- Sole voting/dispositive power: 0 shares
- Shared voting/dispositive power: 22,025 shares
- Filing basis: Passive ownership; certifications state the position was acquired in the ordinary course and not for the purpose of influencing control.
- Reporting structure: LLC is general partner and investment adviser to the Cayman-domiciled master fund; the three individuals are control persons of the LLC. All parties disclaim membership in a group and beneficial ownership except for pecuniary interest.
- Ownership status: Item 5 confirms ownership of <5 % of the class; therefore the position is below the threshold that typically triggers Schedule 13D obligations.
The amendment does not disclose purchase dates, cost basis, or any intention to alter the company’s strategy. Given the <0.5 % stake, the filing is primarily informative and is unlikely to be a market-moving catalyst on its own.